4CPS-130 Evaluation of tixagevimab-cilgavimab in pre-exposure prophylaxis of COVID-19
PA Cáceres, RH Chaves, MN De Sologuren… - 2023 - ejhp.bmj.com
Background and Importance In the context of pre-exposure prophylaxis of COVID-19 in
adults and adolescents aged 12 years and older (> 40 kg), tixagevimab-cilgavimab is …
adults and adolescents aged 12 years and older (> 40 kg), tixagevimab-cilgavimab is …
CP-141 Bosentan treatment for autoimmune diseases
MM Gasque, EL Fabo, MC Elizondo, PF Mateo… - 2015 - ejhp.bmj.com
Background Bosentan, an orphan drug, is a dual endothelin receptor antagonist indicated in
pulmonary hypertension and in the prevention of new digital ulcers (DU) in patients with …
pulmonary hypertension and in the prevention of new digital ulcers (DU) in patients with …
4cps-009 efficacy, safety and economic impact of vedolizumab in ulcerative colitis and crohn's disease
JP Goldaracena, JP Garcia, JAI Becerra, MC Punset… - 2018 - ejhp.bmj.com
Background Treatments for ulcerative colitis (UC) and Crohn's disease (CD) include
conventional agents and tumour necrosis factor-alpha inhibitors (anti-TNFα). A substantial …
conventional agents and tumour necrosis factor-alpha inhibitors (anti-TNFα). A substantial …
DI-088 Everolimus in tuberous sclerosis complex treatment
MPM Gasque, RR Fraile, MC Elizondo, MG Valencia… - 2016 - ejhp.bmj.com
Background Tuberous sclerosis complex (TSC) is an autosomal dominant disease with
variable expressiveness and multisystem involvement. Everolimus, an mTOR inhibitor, is …
variable expressiveness and multisystem involvement. Everolimus, an mTOR inhibitor, is …
[CITATION][C] Análisis de las intervenciones farmacéuticas en pacientes hospitalizados durante el año 2017 en el Complejo Hospitalario de Navarra
I Monteserin Garrastatxu - 2018